Preview

Нефрология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

УСЛОВИЯ РАЗВИТИЯ УРАТНОГО НЕФРОЛИТИАЗА И ПОДХОДЫ К ЕГО МОДЕЛИРОВАНИЮ

https://doi.org/10.24884/1561-6274-2017-21-4-48-54

Полный текст:

Аннотация

В обзоре описаны патофизиологические факторы, способствующие развитию уратного нефролитиаза. Представлены различные подходы к его моделированию. Отмечены наиболее выгодные методики с позиции современных представлений о патогенезе заболевания.

Об авторах

В. Ю. Перфильев
Кафедра фармакологии Алтайского государственного медицинского университета
Россия


Я. Ф. Зверев
Кафедра фармакологии Алтайского государственного медицинского университета
Россия
Проф., д-р мед. наук


А. Ю. Жариков
Кафедра фармакологии Алтайского государственного медицинского университета
Россия
Проф., д-р биол. наук


Список литературы

1. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Advances in chronic kidney disease 2012; 19 (6): 358-371

2. Wu X et al. Two independent mutational events in the loss of urate oxidase during hominoid evolution. Journal of molecular evolution 1992; 34 (1): 78-84

3. Alvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology 2010; 49 (11): 2010-2015

4. Doherty M. New insights into the epidemiology of gout. Rheumatology 2009; 48: ii2-ii8

5. Пытель ЮА, Золотарев ИИ. Уратный нефролитиаз. Медицина, М., 1995; 176 c [Pytel’ YUA, Zolotarev II. Uratnyj nefrolitiaz. M.: Medicina, 1995; 176 s]

6. Burns CM, Wortmann RL. Disorders of purine and pyrimidine metabolism. In: Faci AS, Longo DL, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Principles of Internal Medicine, McGraw-Hill, New York, 2012: 215-219

7. Kratzer JT, Lanaspa MA, Murphy MN et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 2014; 111 (10): 3763-3768

8. Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis The Lancet Neurology 2015; 14 (2): 183-193

9. Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795

10. Зверев ЯФ, Брюханов ВМ. Современный взгляд на механизмы развития уратного нефролитиаза. Клин нефролог 2015; (5-6): 39-47 [Zverev YaF, Bryuhanov VM. Sovremennyj vzglyad na mekhanizmy razvitiya uratnogo nefrolitiaza. Klin nefrolog 2015; (5-6): 39-47]

11. Брюханов ВМ, Зверев ЯФ, Лампатов ВВ. и др. Влияние питьевых режимов на движущие силы кристаллизации при экспериментальном нефролитиазе. Урология 2011; 1: 6-11 [Bryuhanov VM, Zverev YAF, Lampatov VV i dr. Vliyanie pit’evyh rezhimov na dvizhushchie sily kristallizacii pri ehksperimental’nom nefrolitiaze. Urologiya 2011; 1: 6-11]

12. Зверев ЯФ, Брюханов ВМ, Лампатов ВВ, Жариков АЮ. Современные представления о роли физико-химических факторов в патогенезе кальциевого нефролитиаза. Нефрология 2009; 13 (1): 39-50 [Zverev YAF, Bryuhanov VM, Lampatov VV, ZHarikov AYU. Sovremennye predstavleniya o roli fiziko-himicheskih faktorov v patogeneze kal’cievogo nefrolitiaza. Nefrologiya 2009; 13 (1): 39-50]

13. Atan L et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology 2005; 65 (5): 858-861

14. Robertson WG. Renal stones in the tropics. Seminars in nephrology 2003; 23 (1): 77-87

15. Yu TF, Gutman A.B. Uric acid nephrolithiasis in gout. Annals of internal medicine 1967; 67 (6): 1133-1148

16. Барскова ВГ, Мукагова МВ. Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Современная ревматология 2011; 4: 39-43 [Barskova VG, Mukagova MV. Sovremennye predstavleniya o patogeneze i metodah korrekcii uratnogo nefrolitiaza u bol’nyh podagroj. Sovremennaya revmatologiya 2011; 4: 39-43]

17. Alvarez-Nemegyei J et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? The Journal of rheumatology 2005; 32 (11): 2189-2191

18. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. American Journal of Kidney Diseases 2002; 40 (1): 37-42

19. Kramer HJ et al. The association between gout and nephrolithiasis in men: The Health Professionals’ Follow-Up Study. Kidney international 2003; 64 (3): 1022-1026

20. Davidson MB et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. The American journal of medicine 2004; 116 (8): 546-554

21. Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Current rheumatology reports 2007; 9 (3) 251-257

22. Руденская ГЕ, Захарова ЕЮ, Бессонова ЛА и др. Синдром Леша-Найхана: фенотипическое разнообразие и ДНК-диагностика. Медицинская генетика 2010; 9 (9): 41-48 [Rudenskaya GE, Zaharova EYU, Bessonova LA i dr. Sindrom Lesha-Najhana: fenotipicheskoe raznoobrazie i DNK-diagnostika. Medicinskaya genetika 2010; 9 (9): 41-48]

23. Ngo TC, Assimos DG. Uric acid nephrolithiasis: recent progress and future directions. Reviews in urology 2007; 9 (1): 17

24. Talente GM et al. Glycogen storage disease in adults. Annals of internal medicine 1994; 120 (3): 218-226

25. Wilson JM, Young AB, Kelley WN. Hypoxanthine-guanine phosphoribosyltransferase deficiency: the molecular basis of the clinical syndromes. New England Journal of Medicine 1983; 309 (15): 900-910

26. Tsimberidou A, Keating MJ. Hyperuricemic syndromes in cancer patients Hyperuricemic Syndromes: Pathophysiology and Therapy. Karger Publishers, 2004; 147: 47-60

27. Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmacology & therapeutics 2012; 136 (1): 106-130

28. Mullin JW. Nucleation. In: Crystallization. ButterworthHeinemann, Oxford. 1993; 172-201

29. Anzai N et al. Recent advances in renal urate transport: characterization of candidate transporters indicated by genomewide association studies. Clinical and experimental nephrology 2012; 16 (1): 89-95

30. Lipkowitz MS. Regulation of uric acid excretion by the kidney. Current rheumatology reports 2012; 14 (2): 179-188

31. So A, Thorens B. Uric acid transport and disease. The Journal of clinical investigation 2010; 120 (6): 1791-1799

32. Bach MH, Simkin PA. Uricosuric drugs: the once and future therapy for hyperuricemia? Current opinion in rheumatology 2014; 26 (2): 169-175

33. Endou H, Anzai N. Urate transport across the apical membrane of renal proximal tubules. Nucleosides, Nucleotides, and Nucleic Acids 2008; 27 (6-7): 578-584

34. Richette P, Garay R. Novel drug discovery strategies for gout. Expert opinion on drug discovery 2013; 8 (2): 183-189

35. Torralba KD, Jesus E, Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. International journal of rheumatic diseases 2012; 15 (6): 499-506

36. Villegas R et al. Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men’s Health Study. Nutrition, Metabolism and Cardiovascular Diseases 2012; 22 (5): 409-416

37. Кадыров ЗА, Истратов ВГ, Сулейманов СИ. Некоторые вопросы этиологии и патогенеза мочекаменной болезни. Урология 2006; 5: 98-102 [Kadyrov ZA, Istratov VG, Sulejmanov SI. Nekotorye voprosy ehtiologii i patogeneza mochekamennoj bolezni. Urologiya 2006; 5: 98-102]

38. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Current rheumatology reports 2014; 16 (2): 1-8

39. Menon M, Resnick MI. Urinary lithiasis: etiology, diagnosis, and medical management. In: Walsh PC, ed. Campbell’s Urology, 8th ed. Saunders, Philadelphia. 2002; 3229-3305

40. Sakhaee K. Recent advances in the pathophysiology of nephrolithiasis. Kidney international 2009; 75 (6): 585-595

41. Вандер А. Физиология почек. Под ред. Ю.В.Наточина (Пер с англ. Г.А. Лаписа), Питер, СПб., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256. [Vander A. Fiziologiya pochek. Pod red. YU.V.Natochina (Per s angl. G.A. Lapisa), Piter, SPb., 2000. 256 c. (Renal physiology. Ed. Yu.V.Natochin (Translated from English G.A.Lapis). St Petersburg: Piter, 2000. 256.]

42. Kamel KS, Cheema-Dhadli S, Halperin ML. Studies on the pathophysiology of the low urine pH in patients with uric acid stones. Kidney international 2002; 61 (3): 988-994

43. Sakhaee K et al. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney int 2002; 62(3): 971-979

44. Minkowski O. Untersuchungen zur Physiologie und Pathologie der Harnsäure bei Säugethieren. Archiv für experimentelle Pathologie und Pharmakologie 1898; 41 (6): 375-420

45. Bendich A et al. The direct oxidation of adenine in vivo. Journal of Biological Chemistry 1950; 183 (1): 267-277

46. Simmonds HA, Van Acker KJ. Adenine phosphoribosyltransferase deficiency: 2, 8-dihydroxyadenine lithiasis. Metabolic basis of inherited disease Edited by John B. Stanbury et al. 1983

47. Yokozawa T et al. Adenine-induced hyperuricemia and renal damage in rats. Journal of the agricultural chemical society of japan 1982; 56 (8): 655-663

48. Yokozawa T et al. Animal model of adenine-induced chronic renal failure in rats. Nephron 1986; 44 (3): 230-234

49. Yokozawa T et al. Influence of dietary purine on the level of uric acid in the serum and urine. J Jpn Soc Food Nutr 1981; 34: 35-41

50. Yokozawa T et al. Metabolic effects of dietary adenine in rats Journal of the Agricultural Chemical Society of Japan 1981

51. Yokozawa T et al. Metabolic effects of dietary purine and pyrimidine bases in rats. Agricultural and biological chemistry 1983; 47 (6): 1297-1304

52. Yokozawa T, Oura H, Koizumi F 2, 8-Dihydroxyadenine urolithiasis induced by dietary adenine in rats. Nihon Jinzo Gakkai shi 1985; 27 (3): 371-378

53. Yokozawa T, Zheng PD, Oura H. Biochemical features induced by adenine feeding in rats. Polyuria, electrolyte disorders, and 2, 8-dihydroxyadenine deposits. Journal of nutritional science and vitaminology 1984; 30 (3): 245-254

54. Diwan V et al. Adenine-induced chronic kidney and cardiovascular damage in rats. Journal of pharmacological and toxicological methods 2013; 68 (2): 197-207

55. Adachi S, Yoshizawa F, Yagasaki K. Assay systems for screening food and natural substances that have anti-hyperuricemic activity: uric acid production in cultured hepatocytes and purine bodies-induced hyperuricemic model mice. Cytotechnology 2016; 1-8

56. Epstein FH, Pigeon G. Experimental urate nephropathy: studies of the distribution of urate in renal tissue. Nephron 1964; 1 (3): 144-157

57. Stavric B, Johnson WJ, Grice HC. Uric Acid Nephropathy An Experimental Model. Experimental Biology and Medicine 1969; 130 (2): 512-516

58. Stavric B et al. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor. Investigative urology 1973; 11 (1): 3

59. Waisman J et al. Acute hyperuricemic nephropathy in rats. An electron microscopic study. The American journal of pathology 1975; 81 (2): 367

60. Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. Arthritis & Rheumatism 1975; 18 (2): 153-165

61. Schumacher HR, Phelps P, Agudelo CA. Urate crystal induced inflammation in dog joints: sequence of synovial changes. The Journal of rheumatology 1974; 1 (1): 102

62. Schumacher HR, Phelps P. Sequential changes in human polymorphonuclear leukocytes after urate crystal phagocytosis. An electron microscopic study. Arthritis & Rheumatism 1971; 14 (4): 513-526

63. Kim YG et al. Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy. Molecular Medicine 2000; 6 (10): 837

64. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine 2008; 359 (17): 1811-1821

65. Mazzali M et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38 (5): 1101-1106

66. Mazzali M et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. American Journal of Physiology-Renal Physiology 2002; 282 (6): F991-F997

67. Wang R et al. Siwu decoction attenuates oxonate-induced hyperuricemia and kidney inflammation in mice. Chinese Journal of Natural Medicines 2016; 14 (7): 499-507

68. Wu X et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proceedings of the National Academy of Sciences 1994; 91 (2): 742-746

69. Халфина ТН, Максудова АН, Абдракипов РЗ. Современный взгляд на патогенетические механизмы гиперурикемии. Практическая медицина 2012; 8 (64): 66-67 [Halfina TN, Maksudova AN, Abdrakipov RZ. Sovremennyj vzglyad na patogeneticheskie mekhanizmy giperurikemii. Prakticheskaya medicina 2012; 8 (64): 66-67]

70. Martín NE, Nieto VG. Hypouricemia and tubular transport of uric acid. Nefrologia 2011; 31 (1): 44-50

71. Berliner RW et al. The renal mechanism for urate excretion in man. Journal of Clinical Investigation 1950; 29 (4): 396

72. Gutman AB, Yu TF. A three-component system for regulation of renal excretion of uric acid in man. Transactions of the Association of American Physicians 1961; 74: 353

73. Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system. Annals of the rheumatic diseases 1980; 39 (2): 173-179

74. Anzai N et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. Journal of Biological Chemistry 2008; 283 (40): 26834-26838

75. Bibert S et al. Mouse GLUT9: evidences for a urate uniporter. American Journal of Physiology-Renal Physiology 2009; 297 (3): F612-F619

76. Preitner F et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proceedings of the National Academy of Sciences 2009; 106 (36): 15501-15506

77. Preitner F et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. American Journal of Physiology-Renal Physiology 2013; 305 (5): F786-F795

78. Feig DI et al. Serum uric acid: a risk factor and a target for treatment? Journal of the American Society of Nephrology 2006; 17 (4): S69-S73


Для цитирования:


Перфильев В.Ю., Зверев Я.Ф., Жариков А.Ю. УСЛОВИЯ РАЗВИТИЯ УРАТНОГО НЕФРОЛИТИАЗА И ПОДХОДЫ К ЕГО МОДЕЛИРОВАНИЮ. Нефрология. 2017;21(4):48-54. https://doi.org/10.24884/1561-6274-2017-21-4-48-54

For citation:


Perfilev V.Y., Zverev Y.F., Zharikov A.Y. CONDITIONS OF URATE NEPHROLITHIASIS AND APPROACHES TO ITS MODELING. Nephrology (Saint-Petersburg). 2017;21(4):48-54. (In Russ.) https://doi.org/10.24884/1561-6274-2017-21-4-48-54

Просмотров: 4


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)